OAS1: A multiple sclerosis susceptibility gene that influences disease severity

Neurology

Volumn 75, Issue 5, 2010, Pages 411-418

  O'Brien, M ^a   Lonergan, R ^a   Costelloe, L ^a   O'Rourke, K ^a   Fletcher, J M ^b   Kinsella, K ^a   Sweeney, C ^b   Antonelli, G ^c   Mills, K H ^b   O'Farrelly, C ^a   Hutchinson, M ^a   Tubridy, N ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; OLIGOADENYLATE SYNTHETASE 1; SYNTHETASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77955351122     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ebdd2b     Document Type: Article

References (33)

1. Mullan PB, Hosey AM, Buckley NE, et al. The 2,5 oli-goadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-and interferon-'y- mediated apoptosis. Oncogene 2005;24:5492-5501.
2. IFN-/3 Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter-randomised, double blind, placebo-controlled trial. Neurology 1993;43:655-661.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
4. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
5. Rudick RA, Polman CH. Current approaches to the management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009;8:545-549.
6. O'Rourke K, Walsh C, Antonelli G, Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007;13:336-342.
7. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-555.
8. Association of British Neurologists. Guidelines for the Use of Beta-Interferon and Glatiramer Acetate in Multiple Sclerosis. London: Association of British Neurologists; 2001.
9. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-189.
10. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-b in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria.' Ann Neurol 2005;58:840-846.
12. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
15. Kawade Y. Quantitation of neutralisation of interferon by antibody. Methods Enzymol 1986;119:558-573.
16. He J, Feng D, de Vlas SJ, et al. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. BMC Infect Dis 2006;6:106.
17. Bonnevie-Nielsen V, Field LL, Lu S, et al. Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005;76:623-633.
18. Fedetz M, Matesanz F, Caro-Maldonado A, et al. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 2006;68:446-449.
19. Grigoriadis N, Hadjigeorgiou GM. Virus-mediated autoimmunity in multiple sclerosis. J Autoimmune Dis 2006;3:1-8.
20. Ghosh A, Sarkar SN, Rowe TM, Sen GC. A specific isozyme of 2'-5' oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001;276:25447-25455.
21. LimJK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009;5:1-12.
22. Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 2005;54:1588-1591.
23. Ye S, Guo Q, Tang JP, Yang CD, Shen N, Chen SL. Could 2'5'-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study. Clin Rheumatol 2007;26:186-190.
24. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis, Lancet 2003;362:1184-1191.
25. Durelli L, Barbero P, Bergui M, et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neuro-surg Psychiatry 2008;79:646-651.
26. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
27. Petkau AJ, White RA, Ebers GC, et al. IFN/3 Multiple Sclerosis Study Group. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Neurology 2007;68: S16-S22.
28. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36(SUPPL.):S25-S28.
29. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Im-mun 2003;4:411-419. (Pubitemid 38967606)
30. Li CZ, Kato N, Chang JH, et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int 2009;29: 1413-1421.
31. Gilli F, Valentino P, Caldano M, et al. Expression and regulation of IFNa//3 receptor in IFN/3-treated patients with multiple sclerosis. Neurology 2008;71:1940-1947.
32. Killestein J, Hartung H-P. Interferon/3 in multiple sclerosis: predicting response at an early stage. J Neurol Neuro-surg Psychiatry 2008;79:616-617.
33. Rudick RA, Ransohoff RM. Biomarkers for interferon response in MS: are we there yet? Neurology 2008;70:1069-1070.